Find Unlimited Emails.For Free.
Discover prospects, find their business emails, and build your pipeline with Unifers.
Start for FreeVincent Delattre
Senior Director Technology Innovation & Co-founder @ONWARD Medical
Signup · Get unlimited contacts
WORK HISTORY
Senior Director Technology Innovation & Co-founder @ONWARD Medical
Lead the company’s Innovation efforts in R&D, responsible for new product development, new technologies and new indications, Alliance Management, and Intellectual Property generation.
EDUCATION
Centre International de Valbonne
High School, Sciences
EPFL
37, Engineering, specialization in Neurosciences.
SKILLS
ABOUT VINCENT DELATTRE
I am co-founder @ ONWARD Medical (Euronext: ONWD), a company developing neurostimulation solutions to foster recovery after Spinal Cord Injury. Today leading the Company\'s Technology Innovation, I previously served the Company as CEO, COO, VP Program Management and VP Business Development. Key milestones: 2024 - FDA approval of ARC-EX product, company listing on Euronext Paris, exclusive licensing of CEA-Clinatec\'s BCI Technology,2023 - investigational ARC-BCI™ System implantation in humans in clinical feasibility studies2022 - investigational ARC-IM® Neurostimulator implantation in humans in clinical feasibility studies2021 - €100+ M financing raised through a convertible note followed by the company IPO, listing on Euronext Brussels and Amsterdam. 2020 - the company is renamed ONWARD Medical.2019 - acquisition of Neurorecovery Technology inc. a spin-off from UCLA, Caltech and University of Louisville. Additional financing of € 10M The company is renamed GTX Medical. Implantation in humans of the company spinal cord stimulation electrodes2018 - Nature publication demonstrating for the first time in human that motor control can be recovered after complete paralysis.2016 - € 36M series A financing round, enabling the development of a dedicated product line for people with spinal cord injury. Start of STIMO feasibility study, to enable people with spinal cord injury walk again.2015 - company incorporation in Netherlands (G-Therapeutics BV)2014 (Dec)- company incorporation in Switzerland (G-Therapeutics SA), spinning off form EPFLKey numbers- €150+ M raised through private and public financing schemes, equity and loans- grew the company patent portfolio from 4 application to >400 patents and applications through licensing and filings- secured exclusive IP licenses from 9 universities: Caltech, UCLA, Uni of Louisville, Uni of Minnesota, Uni of Calgary, Uni of British Columbia, Uni. of Zurich, CHUV and EPFL and numerous large and small companiesNumerous prizes and awards: Innogrant (2013), Venture Kick I & II (2013, 2014), Venture – Best Business Idea (2014), Venture Leaders (2014), Hello Tomorrow Challenge – Grand Prize (2014), Perl – prix coup de Coeur (2014), Innovation Prize (2014), Welcome Trust feasibility award (2015). I am an engineer with a PhD in Neurosciences (EPFL). My scientific work focuses on the impact of electrical stimulation on mechanisms of neural circuits re-organization. I am the author of numerous high-impact peer reviewed scientific journals: Cell, Nature, Nature Medicine, Nature Communication.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.